Arbutus Biopharma Corp - Asset Resilience Ratio
Arbutus Biopharma Corp (ABUS) has an Asset Resilience Ratio of 25.80% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ABUS working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2025)
This chart shows how Arbutus Biopharma Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ABUS total assets.
Liquid Assets Composition Over Time
This chart breaks down Arbutus Biopharma Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ABUS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $71.52 Million | 25.8% |
| Total Liquid Assets | $71.52 Million | 25.80% |
Asset Resilience Insights
- Very High Liquidity: Arbutus Biopharma Corp maintains exceptional liquid asset reserves at 25.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arbutus Biopharma Corp Industry Peers by Asset Resilience Ratio
Compare Arbutus Biopharma Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual Asset Resilience Ratio data for Arbutus Biopharma Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 77.64% | $73.46 Million | $94.62 Million | +12.12pp |
| 2024-12-31 | 65.52% | $86.29 Million | $131.71 Million | -3.54pp |
| 2023-12-31 | 69.06% | $99.72 Million | $144.40 Million | +9.63pp |
| 2022-12-31 | 59.43% | $116.14 Million | $195.42 Million | +36.92pp |
| 2021-12-31 | 22.51% | $46.03 Million | $204.49 Million | -29.29pp |
| 2020-12-31 | 51.81% | $71.02 Million | $137.08 Million | -4.13pp |
| 2019-12-31 | 55.94% | $59.03 Million | $105.53 Million | +17.47pp |
| 2018-12-31 | 38.47% | $87.67 Million | $227.91 Million | +8.07pp |
| 2017-12-31 | 30.40% | $72.10 Million | $237.20 Million | -8.42pp |
| 2016-12-31 | 38.82% | $107.10 Million | $275.90 Million | +36.78pp |
| 2015-12-31 | 2.04% | $14.53 Million | $712.29 Million | -31.80pp |
| 2014-12-31 | 33.84% | $40.00 Million | $118.20 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $71.72 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $52.60 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $13.70 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $21.02 Million | -- |
| 2009-12-31 | 0.00% | $0.00 | $41.95 Million | -- |
| 2008-12-31 | 11.12% | $4.71 Million | $42.34 Million | -- |
| 2007-12-31 | 0.00% | $0.00 | $24.83 Million | -- |
| 2006-12-31 | 0.00% | $0.00 | $6.03 Million | -- |
| 2005-12-31 | 0.00% | $0.00 | $18.50 Million | -- |
| 2004-12-31 | 0.00% | $0.00 | $41.10 Million | -- |
| 2003-12-31 | 7.19% | $3.65 Million | $50.73 Million | -26.00pp |
| 2002-12-31 | 33.20% | $17.67 Million | $53.22 Million | +0.76pp |
| 2001-12-31 | 32.44% | $21.93 Million | $67.60 Million | -34.98pp |
| 2000-12-31 | 67.41% | $21.93 Million | $32.52 Million | +37.18pp |
| 1999-12-31 | 30.24% | $8.71 Million | $28.80 Million | -5.51pp |
| 1998-12-31 | 35.75% | $5.66 Million | $15.83 Million | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more